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Phosphorylation at serine 10 (S10) is the major posttranslational modification of the tumor 
suppressor p27, and is reduced in both human and mouse atherosclerosis. Moreover, a 
lack of p27-phospho-S10 in apolipoprotein E-null mice (apoE-/-) leads to increased high-
fat diet-induced atherosclerosis associated with endothelial dysfunction and augmented 
leukocyte recruitment. In this study, we analyzed whether p27-phospho-S10 modulates 
additional endothelial functions and associated pathologies. Defective p27-phospho-S10 
increases COX-2 activity in mouse aortic endothelial cells without affecting other key 
regulators of vascular reactivity, reduces endothelium-dependent dilation, and increases 
arterial contractility. Lack of p27-phospho-S10 also elevates aortic COX-2 expression and 
thromboxane A2 production, increases aortic lumen diameter, and aggravates angiotensin 
II-induced abdominal aortic aneurysm development in apoE-/- mice. All these abnormal 
responses linked to defective p27-phospho-S10 are blunted by pharmacological inhibition 
of COX-2. These results demonstrate that defective p27-phospho-S10 modifies endothelial 
behavior and promotes aneurysm formation via COX-2 activation. 
 






The endothelium is a key player in the maintenance of vascular homeostasis. Among other 
functions, endothelial cells (ECs) regulate leukocyte trafficking [1], angiogenesis [2], 
coagulation [3], vascular tone and arterial blood pressure [4]. Endothelial dysfunction leads 
to local and systemic alterations that contribute to cardiovascular diseases, and is strongly 
associated with hypertension [5, 6], a common cardiovascular risk factor. ECs modulate 
the behavior of vascular smooth muscle cells (VSMCs), affecting their contractile capacity 
through the release of a wide variety of vasoactive factors, such as nitric oxide (NO), 
prostaglandins (PGI2, PGE2, etc), and thromboxane (TX). An imbalance in the synthesis of 
these agents, caused by dysfunction of their main enzymatic producers (NO synthases, 
cyclooxygenases, and PG and TX synthases) can lead to hypertension [6] and generate or 
aggravate vascular pathological manifestations. Endothelial dysfunction also promotes 
other vascular disorders, such as atherosclerosis or some types of aneurysm, at least in 
part through overexpression of adhesion molecules that promote leukocyte extravasation 
and accumulation within the inflamed arterial wall [7]. These events can alter the blood 
flow and induce medial degeneration [8], an early event in both atherosclerosis and 
aneurysm.   
 
Cell cycle inhibitors have emerged as important protective agents against vascular disease 
and cardiovascular risk. p27kip1 is a member of the Cip/Kip family of cyclin-dependent 
kinase inhibitors (CKIs) that inhibits VSMC proliferation and migration in vitro [9, 10]. 
Studies in the apolipoprotein E-null mouse model (apoE-/-) demonstrated that loss of p27 
increases the proliferation of VSMCs and macrophages in atherosclerotic vessels and 
exacerbates atherosclerosis progression [11, 12]. Similarly, studies of angiotensin II-
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induced vascular injury in p27-null mice have shown increased cellular proliferation in 
aorta and arterial thickening [13].  
 
The protective effect of p27 on the cardiovascular system is not only related to its classical 
proliferation-dependent activity. p27 has emerged as a versatile protein able to mediate a 
wide range of cellular processes, including cytoskeletal organization [14], cellular migration 
[15], and gene transcription [16]. Some of these properties are modulated by 
posttranslational modification, the most prominent being phosphorylation at serine 10 
(S10) [17]. In previous studies, we demonstrated that loss of p27-phospho-S10 is a 
hallmark of human and mouse atherosclerosis [18]. By crossing athero-susceptible apoE-/- 
mice with p27S10A knock-in mice, which are defective for p27-phospho-S10 [19], we 
found that this phosphorylation protects against endothelial dysfunction and leukocyte 
recruitment, foam cell formation, and early and advanced states of high-fat diet-induced 
atherosclerosis development through cell-cycle-independent mechanisms [18, 20]. 
Whether defective p27-phospho-S10 regulates other aspects of vascular pathophysiology 
remains unknown. To address this question, we investigated here the role of p27-
phospho-S10 in the modulation of vascular reactivity in thoracic aorta and arterioles of the 
cremaster muscle, blood pressure, and the formation of abdominal aortic aneurysms 
(AAA) in apoE-/- mice fed a standard non-atherogenic diet. Our results reveal that loss of 
p27-phospho-S10 promotes endothelial dysfunction and pathological vascular remodeling 







2. MATERIALS AND METHODS 
 
2.1. Mice  
Wild-type and mutant mice used in this study were males on the C57BL/6J genetic 
background. Double mutant apoE-/-p27S10A mice were obtained by crossing apoE-/- 
mice (The Jackson Laboratory, Madison, WI) with p27S10A mice defective for p27-
phospho-S10 [19]. Mice were fed ad libitum a standard diet (LabDiet JL Rat and 
Mouse/Auto 6F 5K67). All mouse procedures conformed to EU Directive 2010/63EU and 
Recommendation 2007/526/EC, enforced in Spanish law under Real Decreto 53/2013. 
Animal protocols were approved by the local ethics committees and the Animal Protection 
Area of the Comunidad Autónoma de Madrid (PROEX 135/14). 
 
2.2. Anesthesia and euthanasia 
For intravital microscopy experiments and osmotic minipump implantation, animals were 
anesthetized with an intraperitoneal injection of a mixture of medetomidine and ketamine 
(0.5 mg/kg and 50 mg/kg, respectively). For ultrasound aorta visualization, animals were 
anesthetized by inhalation of vaporized 2% isoflurane. Mice were sacrificed by cervical 
dislocation or CO2 inhalation.  
 
2.3. Isolation and culture of mouse aortic ECs (mAECs) 
mAECs were isolated as previously described [21]. Briefly, 7 adult mice were sacrificed, 
the aortas were harvested, and adipose tissue and the adventitia were removed. Tissue 
was then cut into ~1 mm rings and placed on 0.5% gelatin coated plates. The rings were 
incubated for 1 week in EC-specific medium (DMEM:F12, Lonza) containing 1% 
penicillin/streptomycin, 0.4mM L-glutamine, 10 mM Hepes, 1 g/ml fungizone, 10% fetal 
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bovine serum (FBS), 0.1 mg/ml heparin (Sigma-Aldrich), and 50 μg/ml EC growth 
supplement (Becton Dickinson). mAECs that had migrated from the rings onto the plate 
were selected after incubation with CD102 antibody (Purified Rat Anti-Mouse CD102 - 
ICAM-2 Monoclonal Antibody, BD Pharmigen) followed by incubation with a secondary 
antibody linked to magnetic beads (Dynabeads Sheep anti-Rat IgG, Invitrogen). Cells were 
collected using a DynaMag-15 Magnet platform (Life Technologies), and were expanded 
at passage 0 in gelatin-coated plates containing mAEC medium. All cells used for assays 
were between passages 4 and 7. 
  
2.4. Western blot 
Proteins from mouse abdominal aorta and mAECs were extracted with cold lysis buffer (50 
mM Tris·Cl, pH 7.2, 1% (w/v) Triton X-100, 0.1% (w/v) SDS, 500 mM NaCl and 10 mM 
MgCl2) supplemented with protease and phosphatase inhibitors (Roche). Polyacrylamide 
gel-electrophoresis and western blot were performed as described [22]. The following 
primary antibodies were used at the indicated dilutions: anti--actin 1/2000 (sc-47778), anti 
ERK-2 1/1000 (sc-1647), anti-iNOS 1/1000 (sc-650), and anti-eNOS 1/1500 (sc-654) from 
Santa Cruz Biotechnology; anti-COX-1 1/1000 (160109) and anti-COX-2 1/1000 (160112) 
from Cayman Chemical. Secondary HRP-conjugated antibodies were from Santa Cruz 
Biotechnologies: anti-IgG-rabbit 1/5000 (sc-2004) and anti-IgG-mouse 1/5000 (sc-2005). 
Immunocomplexes were detected by incubation with Luminata Forte Western HRP 
substrate (Millipore). 
 
2.5. Gene expression studies 
Total RNA from mAECs and mouse whole aortas was purified using TRIzol Reagent 
(Invitrogen). RNA was retrotranscribed with Superscript III First Strand Synthesis Supermix 
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(Invitrogen) and amplified with Power Syber Green PCR Master Mix (Applied Biosystems) 
using the following primers (Fw: Forward; RV: Reverse; 5´to 3´): 
Gene (protein) 
Nos2 (iNOS)   Fw: GGCAGCCTGTGAGACCTTTG  
Rv: GCATTGGAAGTGAAGCGTTTC 
Nos3 (eNOS)  Fw: TCAGCCATCACAGTGTTCCC 
    Rv: ATAGCCCGCATAGCGTATCAG 
COX1 (COX-1)  Fw: TGGCCAAGGTCTACCCCG 
    Rv: CTCTGTACCCAAAGACTGCC 
COX2 (COX-2)  Fw: AGTCTCTCAATGAGTACCGGAAA 
    Rv: AAGTTCTTCAAATGATGTGTACGG 
mPges1 (mPGES1) Fw: AGCACACTGCTGGTCATCAA 
    Rv: TCCACATCTGGGTCACTCCT 
mPges2 (mPGES2) Fw: ACTTCCACTCCCTGCCCTAT 
    Rv: GTTGCAAGCTGTCTCCTTCC 
cPges3 (cPGES)  Fw: GGCAAAGCTTAATTGGCTCA 
    Rv: ATCCTCATCACCACCCATGT 
Ptgis (PTGIS)  Fw: TCCATCCCTATGCCATCTTC 
    Rv: ACTGCCTGCTTCTGTGGAGT 
Tbxas1 (TBXAS1)  Fw: GAGGTGCTGGGACAACGTAT 
    Rv: GCCTCTGCTGTGAACCTTTC 
Gapdh (GAPDH)  Fw: TGTGTCCGTCGTGGATCTGA 
    Rv: CCTGCTTCACCACCTTCTTGAT 
Hprt1 (HGPRT)  Fw: CCTAAGATGAGCGCAAGTTGAA 
    Rv: CCACAGGACTAGAACACCTGCTAA 
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36b4 (RPLP0)  Fw: ACTGGTCTAGGACCCGAGAAG 
    Rv: TCCCACCTTGTCTCCAGTCT 
 
Reactions were conducted in an ABI Prism 7500 Fast System and were analyzed with 
SDS 2.3 software (Applied Biosystems). Gene expression was normalized to the 
housekeeping genes 36b4, Gapdh, and Hprt1. 
 
2.6. COX activity in mAECs 
mAECs (106 cells) were homogenized in cold buffer (0.1 M Tris-HCl, pH 7.8 containing 
1mM EDTA). COX peroxidase activity was determined using the COX Activity Assay Kit 
(760151, Cayman Chemical). When indicated, COX-1 and COX-2 activities were 
distinguished by incubating the samples with the COX-2 inhibitor Dup-697 (provided in the 
kit). 
  
2.7. Wire myography 
Wire myography was performed as previously described [23]. Briefly, thoracic aortas were 
obtained from 11-13-week-old mice and cleaned of fat and connective tissue. Aortic tissue 
was cut into four ~2-mm long rings, which were mounted on two tungsten wires in a wire 
myograph system (620M, DMT) and immersed in 37ºC Krebs Henseleit Solution (KHS: 
115 mM NaCl, 2.5 mM CaCl2, 4.6 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM 
NaHCO3, 11.1 mM glucose, and 0.01 mM EDTA) with constant gassing (95% O2 and 5% 
CO2). Vessel rings were mounted on the wire myograph, and diameter-tension relations 
were determined by stepwise stretching the tissue, increasing its passive diameter by 
augmenting the distance between the wires. Force and distance between the wires were 
recorded in each step. The diameter of vessel segments was calculated from these data 
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when the force is equivalent to 100 mmHg (L100) using the Laplace Equation 
(Tension=[pressure*radius]/thickness) [23]. Arterial segments were then set up at their 
optimal distension (0.9 of L100), which was maintained for the rest of the experiment. After 
stabilization for 30 minutes, arteries were exposed to 120 mM KCl to check their functional 
integrity. Optimal removal of the endothelium was assessed by the inability of 
acetylcholine (10 µM) to induce vasodilation in vessels precontracted with 1 µM 
phenylephrine. Endothelial function was examined by recording dose-dependent 
vasodilation induced by acetylcholine (from 0.1 nM to 10 µM) in aortic rings precontracted 
with 1 μM phenylephrine, and data are presented as a percentage of the initial 
precontraction. Vasoconstriction was studied by exposing the segments to increasing 
doses of phenylephrine (from 1nM to 10µM), and data are presented as a percentage of 
the contraction induced by 120 mM KCl. To determine the role of the endothelium in 
phenylephrine-induced vasoconstriction, experiments were performed with endothelium-
denuded tissue, which was obtained by placing the aortic segment on absorbent 
laboratory countertop paper, letting the inner walls touch, and very carefully rolling the 
segment.  
To evaluate the participation of COX-2 in responses to acetylcholine or phenylephrine, 
dose-response curves were also performed in the presence of 1 µM of the specific COX-2 
inhibitor NS-398 (Abcam).  
 
2.8. Intravital microscopy 
Mouse cremaster muscle was dissected, exteriorized and visualized as described [24]. 
The muscle was cut longitudinally by thermocautery, and the extended muscle was 
positioned on a clear viewing pedestal. During the procedure, the muscle was perfused 
continuously with 37ºC Tyrode’s buffer to maintain physiological conditions. Cremaster 
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arterioles were recorded using a Leica DM6000-FS intravital microscope equipped with an 
Apo 40x NA 1.0 water-immersion objective and a DFC350-FX camera. Vascular 
contraction was induced by intravenous administration of phenylephrine (100 µl, 1 mM). 
Arterioles were recorded from 10 seconds before bolus administration until they recovered 
the basal state. Arteriolar diameters were measured off-line from videotapes using 
SlideBook 5.5 digital microscopy imaging software. The mean diameter during the 10 
seconds before stimulation was considered the baseline state. To inhibit COX-2 activity, 
animals were treated orally with 0.12 mg/day of NS-398 (Abcam) for 3 days prior to 
surgery.   
 
2.9. Prostanoid release  
Thoracic aortas were cut into four ~2-mm long segments, which were immersed in 37ºC 
HEPES buffer (119 mM NaCl, 20 mM HEPES, 4.6 mM KCl, 1 mM MgSO4·7H2O, 0.15 mM 
Na2HPO4·12 H2O, 0.4 mM KH2PO4, 5 mM NaHCO3, 1.2 mM CaCl2·2H2O, 5.5 mM 
glucose). After a 30 min stabilization period, segments were washed twice with 0.2 ml 
HEPES (10 min each). The baseline levels of the prostanoids PGI2, PGE2, and TXA2 were 
quantified in the medium using ELISA kits (Caiman Chemical) to measure their stable 
metabolites 6-keto-PGF1α, 13,14-dihydro-15-keto PGE2, and TXB2, respectively. Fresh 
medium was then added and the arteries were incubated for 2 min with phenylephrine (1 
µM), followed by addition of acetylcholine (10 µM) and incubation for another 8 min. The 
medium was then collected for quantification of stimulated prostanoid release. Collected 






2.10. Blood pressure analysis 
Blood pressure was determined in conscious mice by the tail-cuff method using the BP-
2000 Blood Pressure Analysis System (Visitech). Animals were trained for one week 
before blood pressure measurements. Values were calculated as the mean of 10 single 
measurements per animal at each time point. Mice treated with 50 l of 1 mM 
phenylephrine were previously anesthetized with a mixture of medetomidine and ketamine 
(0.5 mg/kg and 50 mg/kg, respectively). 
 
2.11. Histological and immunofluorescence analysis of thoracic aorta 
Thoracic aortas from male wild-type and p27S10A mice were divided into four 2-mm-long 
segments (numbered 1-4, #1 being the segment more proximal to the heart). For 
histological studies and elastin visualization, the second segment was fixed in 4% 
paraformaldehyde in PBS, embedded in paraffin, and cut into 4-m thick cross-sections. 
Sections were either stained with hematoxylin/eosin for structural studies or analyzed with 
a Leica TCS/SP5 confocal microscope equipped with a 40X objective to visualize the 
autofluorescence emitted by elastin layers upon excitation with an Argon 488 laser.  
To quantify VSMC content, the third thoracic aorta segment was cryoprotected with 15% 
and 30% sucrose (in PBS), embedded in OCT (Tissue-Tek) and stored at -80°C until 
sectioning with a cryostat. Six-m thick sections were defrosted, fixed with 4% 
paraformaldehyde in PBS, and permeabilized during 1h at room temperature with PBS 
containing 0.3% Triton X100, 5% BSA and 5% normal goat serum. Sections were then 
incubated with Cy3-conjugated anti-α-SMC actin (SMA-Cy3 antibody, 1/200, SIGMA) and 
DAPI (1/500, Invitrogen) during 2h at room temperature. Sections were washed, mounted 
with Fluoromount (SIGMA), and stored at 4ºC until image acquisition with a Leica 
TCS/SP5 confocal microscope. All images were acquired using the same laser and 
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photomultiplier settings to obtain maximal projection images of z-stacks covering the whole 
section thickness. Images were analyzed with ImageJ/Fiji software (National Institutes of 
Health) to automatically adjust the threshold for SMA-Cy3 fluorescence signal  by using 
the IsoData algorithm. The mean intensity of the SMA-Cy3 signal above threshold was 
used to quantify the relative VSMC content for each genotype. 
 
2.12. Abdominal aortic aneurysm model 
AAA was induced in 8-week-old male apoE-/- and apoE-/-p27S10A mice fed standard diet 
according to the method developed by Daugherty et al [25]. Briefly, osmotic minipumps 
releasing angiotensin II (1 g/kg/min, Alzet Corp) were implanted subcutaneously and 
maintained for 28 days. Aortic diameter was quantified in live mice at scheduled times 
after minipump implantation with a high-frequency ultrasound VEVO 770 system [26]. 
Aortic dilations were considered AAA when vessel diameter exceeded the baseline 
diameter by more than 50%. For COX-2 inhibition, mice were treated orally with 0.12 
mg/day of NS-398 (Abcam) throughout angiotensin II infusion.  
 
To characterize aneurysms, abdominal aorta was fixed with 4% PFA/PBS, embedded in 
paraffin, and sectioned for histological and immunofluorescence analysis. Collagen 
content was determined by Masson trichrome staining. Macrophage content was 
determined by immunochemistry with a rat anti-Mac3 monoclonal antibody (clone M3/84, 
sc-19991, Santa Cruz Biotechnology) followed by incubation with biotin-conjugated goat 
anti-rat secondary antibody (1/300), sc-2041, Santa Cruz Biotechnology). Mac3 
immunocomplexes were visualized by incubating with streptavidin-HRP (Ref. TS-060-HR, 
LabVision Corporation) and DAB substrate (BUF 021A, AbD SEROTEC). VSMC content 
was determined by immunochemistry with a mouse anti-smooth muscle α-actin (SMA, 
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1/50) monoclonal antibody conjugated to alkaline phosphatase (clone 1A4) followed by 
reaction with Fast Red substrate (both from Sigma). Elastin was visualized using van 
Gieson staining, and elastin breakage was quantified by averaging the number of elastin 
breaks in 3 different sections of each AAA. The extent of AAA lesions and areas positive 
for all components was quantified in at least two sections per aorta by an operator blinded 
to genotype using ImageJ software. The mean value of all sections analyzed were 
represented for each mouse (n=5 mice of each genotype). 
 
2.13. Statistical analysis 
Results are shown as mean ± SEM. Student's t tests were used to compare one variable 
data, followed by Bonferroni corrections as appropriate. Dose-response curves were 
compared using repeated-measures two-way ANOVA with Bonferroni´s multiple 
comparison test. Diameter-tension relations were analyzed by comparing exponential 
growth equation fitting curves with the extra sum-of-squares F test. Differences were 
considered statistically significant at P<0.05. Statistical analysis was performed with 








3.1. Lack of p27-phospho-S10 activates COX-2 in mAECs. We first investigated a 
possible role of p27-phospho-S10 in regulating vasoreactivity by analyzing the expression 
of the synthases of key endothelium-derived vasomodulators. Specifically, we compared 
the expression of eNOS, iNOS, COX-1, and COX-2 in mAECs cultured from wild-type 
mice and p27S10A mice, which are unable to phosphorylate p27 at S10 [19]. Analysis by 
qPCR and western blot revealed no between-genotype differences in mRNA or protein 
expression of eNOS, iNOS, and COX-1; however, p27S10A mAECs showed higher COX-
2 mRNA and protein levels (Fig. 1A,B). Accordingly, p27S10A mAECs showed a 4-fold 
higher COX enzyme activity, which was blunted by treatment with the COX-2-specific 
inhibitor DUP-697 (Fig. 1C). These results demonstrate that the absence of p27-phospho-
S10 promotes COX-2 expression and activity in mAECs. 
 
3.2. Lack of p27-phospho-S10 impairs vasodilation in an endothelial- and COX-2-
dependent manner. We next performed ex vivo wire myography experiments using 
thoracic aorta rings from wild-type and p27S10A mice to assess endothelial-dependent 
vasodilation measured by the ability of the vessel to dilate upon stimulation with 
acetylcholine. This factor activates specific nicotinic receptors on ECs that further induce 
the release of different vasomodulators, such as nitric oxide or COX-2. Acetylcholine-
induced dilation was impaired in aortic segments of p27S10A mice compared with wild-
type controls (Fig. 2A, left). This differential response was endothelium-dependent, since 
endothelial denudation completely abolished acetylcholine-induced dilation of aortic 
segments of both genotypes (Fig. 2A, right). We also found improved vasodilator response 
in aortic segments from p27S10A mice treated with the COX-2-specific inhibitor NS-398, 
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which did not affect the response in wild-type aorta (Fig. 2B). These results indicate that 
defective p27-phospho-S10 impairs endothelium-dependent vasodilation in thoracic aorta 
through COX-2 activation.   
 
3.3. Lack of p27-phospho-S10 increases phenylephrine-induced vascular 
contraction in an endothelial- and COX-2-dependent manner. A major function of 
COX-2 is the modulation of vascular contractility through the production of prostanoids 
[27], and we therefore next assessed the effect of defective p27-phospho-S10 on vascular 
contractility in ex vivo wire myography assays with thoracic aorta rings. Phenylephrine-
induced contractions were stronger in thoracic aortas from p27S10A mice than in those 
from wild-type controls (Fig. 3A, left); however, no between-genotype differences in vessel 
contraction were observed when the experiments were performed with de-endothelialized 
aortic segments (Fig. 3A, right) or in the presence of the COX-2 inhibitor NS-398 (Fig. 3B). 
Higher phenylephrine-induced contractility in arterioles of p27S10A mice was also evident 
from in vivo intravital microscopy of the cremaster muscle (Fig. 3C), and this difference 
was also abolished by NS-398 (Fig. 3D). These results indicate that lack of p27-phospho-
S10 increases arterial contractility due to COX-2-induced endothelial dysfunction.  
 
3.4. Lack of p27-phospho-S10 increases the release of arterial thromboxane. To 
uncover potential mechanisms underlying the contractile hypersensitivity caused by the 
absence of p27-phospho-S10, we carried out ELISAs to determine in thoracic aorta the 
release of PGE2, PGI2, and TXA2, the main vasomodulators produced by vascular COX-2 
activity. We found no between-genotype significant differences in PGE2 and PGI2 release 
(Fig. 3E). Moreover, defective p27-phospho-S10 had no effect on mRNA expression of 
prostaglandin E synthase (PGES) and prostaglandin I2 synthase (PGIS) in aorta (Fig. 3F). 
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In contrast, aortic release of TXA2 was significantly increased in p27S10A mice, this effect 
was blunted by NS-398, and thromboxane A2 synthase 1 (TXAS1) mRNA expression was 
higher in p27S10A aorta (Fig. 3E,F). 
 
3.5. Lack of p27-phospho-S10 does not modify blood pressure but promotes 
outward remodeling in mouse thoracic aorta. We next investigated possible 
pathological consequences of the observed vascular abnormalities in p27S10A mice. We 
first measured blood pressure in wild-type and p27S10A animals, both at baseline and 
upon treatment with increasing doses of the vasoconstrictor phenylephrine. As expected, 
phenylephrine strongly increased systolic and diastolic blood pressure (Fig. 4A). 
Surprisingly, however, lack of p27-phospho-S10 did not significantly affect blood pressure 
in any experimental condition (Fig. 4A). These results suggested that compensatory 
mechanisms prevent the predicted increase in blood pressure in p27S10 mice. To assess 
this possibility, we analyzed the thoracic aorta by microscopy and wire myography. 
Comparison of specimens from wild-type and p27S10A mice revealed no differences in 
the number of elastin layers in the media (an average of 5.1 layers in both genotypes) (Fig. 
4B), media-to-lumen ratio (Fig. 4C), or in the relative amount of VSMCs (Fig. 4B,D). 
However, wire myography studies revealed a right-shift in the diameter-tension relations 
and significantly larger diameter under physiological conditions (100 mm Hg) in p27S10A 
mice (Fig. 4E). These results indicate that lack of p27-phospho-S10 induces outward 
remodeling in the thoracic aorta. 
 
3.6. Lack of p27-phospho-S10 promotes abdominal aortic aneurysm formation via 
COX-2 activation. AAA is characterized by excessive aortic dilation caused by structural 
defects in the arterial wall [28]. In light of our findings and previous studies revealing 
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protective effects of p27-phospho-S10 against pathological vascular remodeling [18, 20], 
we investigated the potential involvement of p27-phospho-S10 in AAA initiation and 
development, using the angiotensin II infusion model for AAA generation in 8-week-old 
apoE-/- and apoE-/-p27S10A mice fed normal diet. Ultrasound visualization of abdominal 
aortas revealed more pronounced aortic dilation over time in apoE-/-p27S10A mice than in 
apoE-/- controls (Fig. 5A). In addition, the incidence of AAA and associated mortality in the 
first days were higher in apoE-/-p27S10A mice (Fig. 5B). These results demonstrate 
accelerated AAA development and worse disease prognosis in apoE-/- mice unable to 
phosphorylate p27 at S10A. 
 
Histological analysis of AAA lesions in apoE-/- and apoE-/-p27S10A mice showed that lack 
of p27-phospho-S10 does not significantly alter key parameters in aneurysmal lesions, 
including the percentage of total area occupied by collagen, macrophage, and VSMCs, as 
well as elastin breakage (Fig. 6A). Because hypertension is associated with AAA 
development [29] and p27-phospho-S10 modulates vascular reactivity (Fig. 2 and 3), we 
also evaluated blood pressure. As expected, angiotensin II administration increased blood 
pressure in both apoE-/- and apoE-/-p27S10A mice; however, the increase did not differ 
between the two groups, indicating that it was independent of p27 phosphorylation status 
(Fig. 6B).  
 
Increased COX-2 activity, as observed in the absence of p27-phospho-S10 (Fig. 1), 
correlates with AAA formation in humans [30] and mouse models [31, 32]. We therefore 
analyzed COX-2 expression in the abdominal aorta of angiotensin II-treated apoE-/- and 
apoE-/-p27S10A mice. Western blot analysis demonstrated above-normal COX-2 
expression in the abdominal aorta of both control and angiotensin II-treated apoE-/-
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p27S10A mice (Fig. 7A), as well as in cultures of angiotensin II-treated mAECs (Fig. 7B). 
Accordingly, treatment of apoE-/-p27S10A mice with the COX-2 inhibitor NS-398 
prevented the angiotensin II-dependent increase in aortic diameter, AAA incidence, and 







Previous studies have demonstrated a protective role of p27 in the cardiovascular system. 
As a growth suppressor, p27 limits high-fat diet-induced atherosclerosis progression in 
apoE-/- mice by reducing hyperproliferation of both VSMCs and macrophages [11, 12]. 
p27 also inhibits atherosclerosis in fat-fed apoE-/- mice through cell cycle-independent 
mechanisms mediated by its phosphorylation at S10, which regulates macrophage foam 
cell formation, endothelial function, and arterial leukocyte infiltration in a RhoA/ROCK-
dependent manner [18, 20]. To explore new functions of p27-phospho-S10 in the vascular 
system, we investigated here its possible role in the regulation of vascular tone, blood 
pressure, and AAA formation in mice maintained on a control low-fat diet to minimize the 
potential interference of atherosclerosis development. Our results establish a link between 
p27-phospho-S10 status and COX-2 expression and activity that has pathophysiological 
implications. In pilot experiments assessing the expression of the synthases of key 
endothelium-derived vasomodulators, we found COX-2 hyperactivation in mAECs from 
mice unable to phosphorylate p27 at S10, which exhibited impaired endothelial-dependent 
dilation and elevated contractility in thoracic aorta and arterioles of the cremaster muscle. 
Both reduced vasodilation and increased vasoconstriction in p27S10A mice were reversed 
upon treatment with the specific COX-2 inhibitor NS-398. A link between the endothelium 
and the elevated vasoconstriction in p27S10A mice was further supported by the 
restoration of normal contraction in de-endothelialized vessels. Mice lacking p27-phospho-
S10 had normal blood pressure, but exhibited higher susceptibility to AAA formation via 
COX-2 hyperactivation.  
 
In most tissues and cell types, COX-2 is usually expressed at very low levels, with 
expression increasing rapidly in response to inflammatory signals [33]. However, COX-2 is 
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constitutively expressed in the endothelium and regulates vascular tone as a major 
producer of the vasodilator PGI2. In diseases such as diabetes and hypertension, COX-2 
activity can compensate endothelial dysfunction by increasing PGI2 production [34, 35]. 
COX-2 inhibition increases vasoconstriction by reducing PGI2 and PGE2 production [36]. 
Other studies reported that COX-2 induction in mouse ECs is linked to increased 
production of vasocontractile prostanoids [37-41]. Moreover, COX-2 increases the 
production of the vasoconstrictor TXA2 in inflammatory conditions [42]. We therefore 
hypothesized that COX-2 overexpression caused by loss of p27-phospho-S10 would affect 
vasomotor responses. We found that COX-2 activity contributes to the below-normal 
endothelium-dependent vasodilation in thoracic aortas from p27S10A mice. We also 
observed an association between the elevated COX-2 activity in p27S10A mAECs and 
above-normal contractility in thoracic aorta and arterioles of the cremaster muscle, 
detected by ex vivo wire myography and in vivo intravital microscopy, respectively.  The 
altered vasomotor responses in p27S10A mice were also associated with above-normal 
TXAS1 expression and TXA2 release in aorta, without significant changes in other COX-2-
derived prostanoids, including PGE2 and PGI2 and their respective synthases PGES and 
PGIS. 
 
Our results show that vasomotor alterations in p27S10A mice are not associated to 
increased blood pressure, either without stimulation or after induction of hypertension with 
phenylephrine. Importantly, blood pressure is modulated by vascular tone, but also by 
vascular structure. Adaptive changes in the vessel wall can occur to maintain the vessel 
under optimal mechanical conditions, thus preventing increased blood pressure [43]. We 
hypothesize that the outward remodeling observed in p27S10A might be such a 
mechanism that prevents high blood pressure. Our wire myography studies revealed an 
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association between defective p27-phospho-S10 and increased passive thoracic aortic 
diameter, without changing the media-to-lumen ratio or relative VSMC content. This vessel 
remodeling could be an adaptive response to the dysfunctional endothelium, which could 
in part, prevent hypertension in p27S10A animals but might predispose to other vascular 
pathologies. Further studies are required to investigate in detail other possible vascular 
alterations induced by defective p27-phospho-S10. 
 
The vascular alterations in p27S10A mice concomitant to COX-2 hyperactivation, together 
with the association of COX-2 with aneurysm formation [31, 44, 45], prompted us to 
investigate the involvement of defective p27-phospho-S10 in COX-2-mediated AAA 
development in apoE-/- mice fed a non-atherogenic control diet. We found higher aortic 
diameter, AAA incidence, and associated mortality in angiotensin II-treated apoE-/-
p27S10A mice than in apoE-/- controls. This phenotype was not accompanied by elevated 
blood pressure or increased leukocyte infiltration of the aneurysms, but was associated 
with increased expression of COX-2, as revealed by western blot analysis of abdominal 
aorta. Remarkably, treatment with NS-398 inhibited AAA formation and blocked the 
associated increased mortality in angiotensin II-treated apoE-/-p27S10A mice. We 
therefore conclude that defective p27-phospho-S10 accelerates AAA development in 
apoE-/- mice via COX-2 hyperactivation. Of note, we observed a minor increase in 
mortality in apoE-/- mice treated with NS-398 compared with untreated controls (Fig. 5B 
versus Fig. 7C), consistent with previous studies suggesting side effects of long term 







Our findings demonstrate new vascular implications of loss of p27-phospho-S10, which 
leads to impaired endothelial-dependent vasodilation, augmented vasoconstrictor 
responses, outward remodeling in thoracic aorta, and increased AAA susceptibility via 
COX-2 hyperactivation, thus identifying new functions of the multifaceted p27. Together 
with our earlier demonstration of increased atherosclerosis in fat-fed apoE-/-p27S10A mice 
[18, 20], these findings suggest that drugs developed to increase p27-phospho-S10 might 




We thank Simon Bartlett for English editing, Fátima Sánchez-Cabo for help with statistical 
analysis, and the CNIC Animal Facility for animal care. This study was supported by the 
Spanish Ministerio de Economía, Industria y Competitividad (MEIC, grants SAF2013-
46663-R and SAF2016-79490-R), and by the Instituto de Salud Carlos III (grants 
RD12/0042/0028, RD12/0042/22 and PI1100406), with co-funding from the Fondo 
Europeo de Desarrollo Regional (FEDER). P.M-S. was supported by a FPU predoctoral 
fellowship from the Spanish Ministerio de Educación (REF. AP2009-01833), C.R. by a 
MEIC postdoctoral contract (REF. FPDI-2013-17423), and L.d.C. by a Jordi Soler 
postdoctoral grant from the Red de Investigación Cardiovascular (RETIC Program, 
Instituto de Salud Carlos III). The CNIC is supported by the MEIC and the Pro-CNIC 
Foundation, and is a Severo Ochoa Center of Excellence (MEIC award SEV-2015-0505).  
 
CONFLICTS OF INTEREST 




[1] Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev 
Immunol 2007; 7:803-15. 
[2] Lamalice L, Le Boeuf F, Huot J. Endothelial cell migration during angiogenesis. Circ 
Res 2007; 100:782-94. 
[3] van Hinsbergh VW. Endothelium--role in regulation of coagulation and inflammation. 
Semin Immunopathol 2012; 34:93-106. 
[4] Feletou M, The Endothelium: Part 1: Multiple functions of the endothelial cells-Focus on 
endothelium-derived vasoactive mediators, San Rafael (CA), 2011. 
[5] Puddu P, Puddu GM, Zaca F, Muscari A. Endothelial dysfunction in hypertension. Acta 
Cardiol 2000; 55:221-32. 
[6] Dharmashankar K, Widlansky ME. Vascular endothelial function and hypertension: 
insights and directions. Curr Hypertens Rep 2010; 12:448-55. 
[7] Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of 
atherosclerosis. Nature 2011; 473:317-25. 
[8] O'Rourke M. Mechanical principles in arterial disease. Hypertension 1995; 26:2-9. 
[9] Diez-Juan A, Andres V. Coordinate control of proliferation and migration by the 
p27Kip1/cyclin-dependent kinase/retinoblastoma pathway in vascular smooth muscle 
cells and fibroblasts. Circ Res 2003; 92:402-10. 
[10] Castro C, Diez-Juan A, Cortes MJ, Andres V. Distinct regulation of mitogen-activated 
protein kinases and p27Kip1 in smooth muscle cells from different vascular beds. A 
potential role in establishing regional phenotypic variance. J Biol Chem 2003; 
278:4482-90. 
[11] Diez-Juan A, Andres V. The growth suppressor p27(Kip1) protects against diet-
induced atherosclerosis. Faseb J 2001; 15:1989-95. 
[12] Diez-Juan A, Perez P, Aracil M, Sancho D, Bernad A, Sanchez-Madrid F, et al. 
Selective inactivation of p27(Kip1) in hematopoietic progenitor cells increases 
neointimal macrophage proliferation and accelerates atherosclerosis. Blood 2004; 
103:158-61. 
[13] Kanda T, Hayashi K, Wakino S, Homma K, Yoshioka K, Hasegawa K, et al. Role of 
Rho-kinase and p27 in angiotensin II-induced vascular injury. Hypertension 2005; 
45:724-9. 
[14] Belletti B, Pellizzari I, Berton S, Fabris L, Wolf K, Lovat F, et al. p27kip1 controls cell 
morphology and motility by regulating microtubule-dependent lipid raft recycling. Mol 
Cell Biol 2010; 30:2229-40. 
[15] Besson A, Gurian-West M, Schmidt A, Hall A, Roberts JM. p27Kip1 modulates cell 
migration through the regulation of RhoA activation. Genes Dev 2004; 18:862-76. 
[16] Pippa R, Espinosa L, Gundem G, Garcia-Escudero R, Dominguez A, Orlando S, et al. 
p27Kip1 represses transcription by direct interaction with p130/E2F4 at the promoters 
of target genes. Oncogene 2012; 31:4207-20. 
24 
 
[17] Ishida N, Kitagawa M, Hatakeyama S, Nakayama K. Phosphorylation at serine 10, a 
major phosphorylation site of p27(Kip1), increases its protein stability. J Biol Chem 
2000; 275:25146-54. 
[18] Fuster JJ, Gonzalez-Navarro H, Vinue A, Molina-Sanchez P, Andres-Manzano MJ, 
Nakayama KI, et al. Deficient p27 phosphorylation at serine 10 increases 
macrophage foam cell formation and aggravates atherosclerosis through a 
proliferation-independent mechanism. Arterioscler Thromb Vasc Biol 2011; 31:2455-
63. 
[19] Kotake Y, Nakayama K, Ishida N, Nakayama KI. Role of serine 10 phosphorylation in 
p27 stabilization revealed by analysis of p27 knock-in mice harboring a serine 10 
mutation. J Biol Chem 2005; 280:1095-102. 
[20] Molina-Sanchez P, Chevre R, Rius C, Fuster JJ, Andres V. Loss of p27 
phosphorylation at Ser10 accelerates early atherogenesis by promoting leukocyte 
recruitment via RhoA/ROCK. J Mol Cell Cardiol 2015; 84:84-94. 
[21] Molina-Sanchez P, Andres V. Isolation of mouse primary aortic endothelial cells by 
selection with specific antibodies. Methods Mol Biol 2015; 1339:111-7. 
[22] Gonzalez-Navarro H, Vinue A, Vila-Caballer M, Fortuno A, Beloqui O, Zalba G, et al. 
Molecular mechanisms of atherosclerosis in metabolic syndrome: role of reduced 
IRS2-dependent signaling. Arterioscler Thromb Vasc Biol 2008; 28:2187-94. 
[23] del Campo L, Ferrer M. Wire myography to study vascular tone and vascular structure 
of isolated mouse arteries. Methods Mol Biol 2015; 1339:255-76. 
[24] Rius C, Sanz MJ. Intravital microscopy in the cremaster muscle microcirculation for 
endothelial dysfunction studies. Methods Mol Biol 2015; 1339:357-66. 
[25] Daugherty A, Manning MW, Cassis LA. Angiotensin II promotes atherosclerotic 
lesions and aneurysms in apolipoprotein E-deficient mice. J Clin Invest 2000; 
105:1605-12. 
[26] Martin-McNulty B, Vincelette J, Vergona R, Sullivan ME, Wang YX. Noninvasive 
measurement of abdominal aortic aneurysms in intact mice by a high-frequency 
ultrasound imaging system. Ultrasound Med Biol 2005; 31:745-9. 
[27] Caughey GE, Cleland LG, Penglis PS, Gamble JR, James MJ. Roles of 
cyclooxygenase (COX)-1 and COX-2 in prostanoid production by human endothelial 
cells: selective up-regulation of prostacyclin synthesis by COX-2. J Immunol 2001; 
167:2831-8. 
[28] Curci JA, Thompson RW. Adaptive cellular immunity in aortic aneurysms: cause, 
consequence, or context? J Clin Invest 2004; 114:168-71. 
[29] Forsdahl SH, Singh K, Solberg S, Jacobsen BK. Risk factors for abdominal aortic 
aneurysms: a 7-year prospective study: the Tromso Study, 1994-2001. Circulation 
2009; 119:2202-8. 
[30] Holmes DR, Wester W, Thompson RW, Reilly JM. Prostaglandin E2 synthesis and 
cyclooxygenase expression in abdominal aortic aneurysms. J Vasc Surg 1997; 
25:810-5. 
[31] Ghoshal S, Loftin CD. Cyclooxygenase-2 inhibition attenuates abdominal aortic 
aneurysm progression in hyperlipidemic mice. PLoS One 2012; 7:e44369. 
25 
 
[32] King VL, Trivedi DB, Gitlin JM, Loftin CD. Selective cyclooxygenase-2 inhibition with 
celecoxib decreases angiotensin II-induced abdominal aortic aneurysm formation in 
mice. Arterioscler Thromb Vasc Biol 2006; 26:1137-43. 
[33] Seibert K, Masferrer JL. Role of inducible cyclooxygenase (COX-2) in inflammation. 
Receptor 1994; 4:17-23. 
[34] Nacci C, Tarquinio M, De Benedictis L, Mauro A, Zigrino A, Carratu MR, et al. 
Endothelial dysfunction in mice with streptozotocin-induced type 1 diabetes is 
opposed by compensatory overexpression of cyclooxygenase-2 in the vasculature. 
Endocrinology 2009; 150:849-61. 
[35] Meeking DR, Browne DL, Allard S, Munday J, Chowienczyck PJ, Shaw KM, et al. 
Effects of cyclo-oxygenase inhibition on vasodilatory response to acetylcholine in 
patients with type 1 diabetes and nondiabetic subjects. Diabetes care 2000; 23:1840-
3. 
[36] Foudi N, Louedec L, Cachina T, Brink C, Norel X. Selective cyclooxygenase-2 
inhibition directly increases human vascular reactivity to norepinephrine during acute 
inflammation. Cardiovasc Res 2009; 81:269-77. 
[37] Alvarez Y, Briones AM, Balfagon G, Alonso MJ, Salaices M. Hypertension increases 
the participation of vasoconstrictor prostanoids from cyclooxygenase-2 in 
phenylephrine responses. J Hypert 2005; 23:767-77. 
[38] Blanco-Rivero J, Cachofeiro V, Lahera V, Aras-Lopez R, Marquez-Rodas I, Salaices 
M, et al. Participation of prostacyclin in endothelial dysfunction induced by 
aldosterone in normotensive and hypertensive rats. Hypertension 2005; 46:107-12. 
[39] Heymes C, Habib A, Yang D, Mathieu E, Marotte F, Samuel J, et al. Cyclo-
oxygenase-1 and -2 contribution to endothelial dysfunction in ageing. Br J Pharmacol 
2000; 131:804-10. 
[40] Shi Y, Vanhoutte PM. Oxidative stress and COX cause hyper-responsiveness in 
vascular smooth muscle of the femoral artery from diabetic rats. Br J Pharmacol 
2008; 154:639-51. 
[41] Virdis A, Colucci R, Versari D, Ghisu N, Fornai M, Antonioli L, et al. Atorvastatin 
prevents endothelial dysfunction in mesenteric arteries from spontaneously 
hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids. 
Hypertension 2009; 53:1008-16. 
[42] Grandel U, Fink L, Blum A, Heep M, Buerke M, Kraemer HJ, et al. Endotoxin-induced 
myocardial tumor necrosis factor-alpha synthesis depresses contractility of isolated 
rat hearts: evidence for a role of sphingosine and cyclooxygenase-2-derived 
thromboxane production. Circulation 2000; 102:2758-64. 
[43] Martinez-Lemus LA, Hill MA, Meininger GA. The plastic nature of the vascular wall: a 
continuum of remodeling events contributing to control of arteriolar diameter and 
structure. Physiology 2009; 24:45-57. 
[44] Hasan D, Hashimoto T, Kung D, Macdonald RL, Winn HR, Heistad D. Upregulation of 
cyclooxygenase-2 (COX-2) and microsomal prostaglandin E2 synthase-1 (mPGES-1) 




[45] Miralles M, Wester W, Sicard GA, Thompson R, Reilly JM. Indomethacin inhibits 
expansion of experimental aortic aneurysms via inhibition of the cox2 isoform of 
cyclooxygenase. J Vasc Surg 1999; 29(5):884-92; discussion 892-3. 
[46] Cannon CP, Cannon PJ. Physiology. COX-2 inhibitors and cardiovascular risk. 




Figure 1: Lack of p27-phospho-S10 causes endothelial COX-2 hyperactivation. (A) 
qPCR analysis of iNOS (Nos2), eNOS (Nos3), COX-1, and COX-2 in mAECs from wild-
type and p27S10A mice (n=3 per genotype). (B) Representative western blot and 
quantification of vasomodulator synthases in mAECs from wild-type and p27S10A mice 
(n=2 per genotype, 2 duplicates). (C) COX activity in wild-type and p27S10A mAECs 
without treatment and upon treatment with the COX-2 inhibitor DUP 697 (n=2 per 
genotype, 2 technical replicates performed). Results are expressed relative to untreated 
wild-type cells. 
 
Figure 2: Lack of p27-phospho-S10 impairs endothelium-dependent acetylcholine-
induced vasodilation in a COX-2-dependent manner. Thoracic aorta segments from 
wild-type and p27S10A mice were mounted on a wire myograph to examine acetylcholine-
induced dilation. Data are presented as a percentage of the contraction induced by 1µM 
phenylephrine. (A) Vessel segments were intact (n=7 per genotype) or denuded (n=7 wild-
type; n=8 p27S10A). (B) Effect of COX-2 inhibition with 1 M NS-398 on acetylcholine-
induced vasodilator response (n=6 wild-type; n=7 p27S10A). 
 
Figure 3: Lack of p27-phospho-S10 increases arterial contractility and TXA2 release. 
(A, B) Wire myography analysis of phenylephrine-induced contraction of thoracic aorta 
segments from wild-type and p27S10A mice. Vessels examined in A had an intact 
endothelium (left: n=5 wild-type; n=7 p27S10A) or had the endothelium removed (right: 
n=7 wild-type; n=6 p27S10A). Experiments in B were performed with vessels with intact 
endothelium that were incubated with 1 M NS-398 to inhibit COX-2 (n=6 wild-type; n=6 
p27S10A). Data are presented as a percentage of the contraction induced by 120 mM KCl. 
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(C, D) Intravital microscopy of cremaster arteriole contraction in wild-type and p27S10A 
mice in response to 100 M phenylephrine (C: n=7 per genotype) and after treatment with 
NS-398 (D: n=8 wild-type; n=6 p27S10A). Results in A-D are presented as the percentage 
of the arterial diameter without treatment. (E) Relative release of PGE2, PGI2, and TXA2 
induced by 1µM phenylephrine/10µM acetylcholine in thoracic aorta from wild-type and 
p27S10A mice. Results are expressed as the ratio of induced to baseline release (=1). 
PGE2: n=5 wild-type, n=6, p27S10A; PGI2: n=17 wild-type, n=17 p27S10A; TXA2: n=8 
wild-type, n=9 p27S10A; TXA2 + NS-398: n=10 wild-type, n=10 p27S10A. (F) qPCR 
analysis of major prostanoid production enzymes in aortas from wild-type (n=5) and 
p27S10A (n=4) mice. Results are expressed relative to wild-type mice. 
 
Figure 4: Lack of p27-phospho-S10 does not alter blood pressure but induces 
outward remodeling in thoracic aorta. (A) Systolic, diastolic, and mean blood pressure 
(BP) in wild-type mice (n=3) and p27S10A mice (n=3) without treatment and after 
phenylephrine administration (50 l of 0.1 mM and 1 mM stock). (B) Representative 
images of thoracic aorta sections from wild-type and p27S10A mice showing 
hematoxylin/eosin staining, and confocal microscopy for autofluorescence of elastin fibers 
and SMA+DAPI staining. (C) Media-to-lumen ratio in thoracic aorta expressed as medial 
area/luminal perimeter (n=5 wild-type, n=4 p27S10A). (D) Relative VSMC content in SMA-
Cy3-immunostained sections of thoracic aorta from wild-type and p27S10A mice (n=5 per 
genotype), calculated as mean intensity of the fluorescent signal (A.U.: arbitrary units). (E) 
Diameter–force curves and aortic diameter determined by wire myography at 100 mmHg 




Figure 5: Lack of p27-phospho-S10 aggravates angiotensin II-induced AAA in mice. 
apoE-/- mice and apoE-/-p27S10A mice fed control diet. (A) Left, Ultrasound-determined 
abdominal aorta diameter at baseline, and after implantation of angiotensin II (AngII) 
minipumps for the indicated time. Results are shown for the 9 mice of each genotype that 
survived throughout the 28 days of AngII infusion. Right, Representative ultrasound 
images of abdominal aorta at baseline and after 24 days of AngII treatment. (B) AAA 
incidence and survival curve (n=12 per genotype).  
 
Figure 6: Lack of p27-phospho-S10 does not modify AAA composition or blood 
pressure in angiotensin II-treated apoE-/- mice. apoE-/- and apoE-/-p27S10A mice fed 
control diet. (A) Relative content of collagen, macrophages, and VSMCs, and number of 
elastin breaks in AAA lesions in apoE-/- and apoE-/-p27S10A mice 28 days after 
angiotensin II infusion (n=5 per genotype). Representative section stainings are shown in 
the lower images. Asterisks mark luminal areas. (B) Systolic, diastolic, and mean blood 
pressure in apoE-/- and apoE-/-p27S10A mice at baseline and during angiotensin II 
treatment (n=6 per genotype).  
 
Figure 7: Lack of p27-phospho-S10 promotes AAA formation through COX-2 
overexpression. (A) Western blot analysis of COX-2 protein content in abdominal aortas 
of control diet-fed apoE-/- and apoE-/-p27S10A mice at baseline and after 28 days of 
angiotensin II (AngII) treatment. Two samples were analyzed for each experimental 
condition and two western blot were performed. A representative blot is shown and the 
chart shows relative quantification. (B) Western blot analysis of COX-2 in wild-type mAECs 
without treatment (control) or treated with 1 mM AngII for 2 h. Two different preparations of 
mAECs were analyzed and a representative western blot is shown. (C) Left, Maximal 
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aortic diameter in apoE-/- and apoE-/-p27S10A mice treated with NS-398 at baseline and 
after AngII infusion for the indicated time. Results are shown for the mice of each genotype 
that survived throughout the 28 days of AngII infusion (n=8 apoE-/-, n=7 apoE-/-p27S10A). 
Middle, AAA incidence in NS-398-treated apoE-/- and apoE-/- mice infused with AngII for 
the indicated times. Right, Survival curves for NS-398-treated apoE-/- and apoE-/-
p27S10A mice infused with AngII for 28 days (n=15 apoE-/-, n=11 apoE-/-p27S10A).  
